CERS Stock Overview
Operates as a biomedical products company. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Cerus Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.79 |
| 52 Week High | US$2.59 |
| 52 Week Low | US$1.38 |
| Beta | 1.2 |
| 11 Month Change | 7.19% |
| 3 Month Change | -24.79% |
| 1 Year Change | 8.48% |
| 33 Year Change | -74.36% |
| 5 Year Change | -58.76% |
| Change since IPO | -85.24% |
Recent News & Updates
Cerus Corporation (NASDAQ:CERS) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Sep 26
Analysts Are Upgrading Cerus Corporation (NASDAQ:CERS) After Its Latest Results
Aug 04Cerus Corporation's (NASDAQ:CERS) 30% Jump Shows Its Popularity With Investors
Jul 18Recent updates
Cerus Corporation (NASDAQ:CERS) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Sep 26Analysts Are Upgrading Cerus Corporation (NASDAQ:CERS) After Its Latest Results
Aug 04Cerus Corporation's (NASDAQ:CERS) 30% Jump Shows Its Popularity With Investors
Jul 18Does Cerus (NASDAQ:CERS) Have A Healthy Balance Sheet?
Jul 12The Cerus Corporation (NASDAQ:CERS) First-Quarter Results Are Out And Analysts Have Published New Forecasts
May 05Here's Why Cerus (NASDAQ:CERS) Can Afford Some Debt
Apr 12Cerus Corporation (NASDAQ:CERS) Stock Rockets 29% But Many Are Still Ignoring The Company
Mar 07Slammed 29% Cerus Corporation (NASDAQ:CERS) Screens Well Here But There Might Be A Catch
Jan 18Health Check: How Prudently Does Cerus (NASDAQ:CERS) Use Debt?
Oct 06Is Cerus (NASDAQ:CERS) A Risky Investment?
Jul 07Slammed 32% Cerus Corporation (NASDAQ:CERS) Screens Well Here But There Might Be A Catch
May 12Cerus: Technical Support Fades, Investment Case Weakens (Technical Analysis)
Sep 29Cerus GAAP EPS of -$0.05 beats by $0.02, revenue of $47.63M beats by $4.87M
Aug 04Cerus: Lacks Conviction Against Macro Backdrop, Technicals Supportive Of Near-Term Upside
Jul 14Is Cerus (NASDAQ:CERS) Using Debt In A Risky Way?
Jul 06Is Cerus (NASDAQ:CERS) Using Debt Sensibly?
Mar 17Cerus Corporation: Outperforming And Gaining Momentum
Jan 28Shareholder Returns
| CERS | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 4.1% | 1.5% | 2.2% |
| 1Y | 8.5% | 20.8% | 31.6% |
Return vs Industry: CERS underperformed the US Medical Equipment industry which returned 20.9% over the past year.
Return vs Market: CERS underperformed the US Market which returned 31.7% over the past year.
Price Volatility
| CERS volatility | |
|---|---|
| CERS Average Weekly Movement | 9.3% |
| Medical Equipment Industry Average Movement | 8.1% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CERS has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: CERS's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1991 | 631 | Obi Greenman | www.cerus.com |
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
Cerus Corporation Fundamentals Summary
| CERS fundamental statistics | |
|---|---|
| Market cap | US$332.43m |
| Earnings (TTM) | -US$19.72m |
| Revenue (TTM) | US$176.23m |
1.9x
P/S Ratio-16.9x
P/E RatioIs CERS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CERS income statement (TTM) | |
|---|---|
| Revenue | US$176.23m |
| Cost of Revenue | US$78.13m |
| Gross Profit | US$98.10m |
| Other Expenses | US$117.82m |
| Earnings | -US$19.72m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.11 |
| Gross Margin | 55.66% |
| Net Profit Margin | -11.19% |
| Debt/Equity Ratio | 153.6% |
How did CERS perform over the long term?
See historical performance and comparison